On October 6, 2026 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported the presentation of new clinical research at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place from October 23-27 in Madrid, Spain. Highlights from the company’s 10 abstracts will cover new data and analyses from trials in cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC), ovarian cancer, melanoma and cancer-associated thrombosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At ESMO (Free ESMO Whitepaper), we look forward to sharing data across a range of conditions reflecting the breadth of our research," said Israel Lowy, M.D., Ph.D., Clinical Development Unit Head, Oncology, at Regeneron. "For the first time, we’re showcasing how our work extends beyond the treatment of cancer itself, and addresses some of the complex challenges patients face as a result of their disease. Together, these data reflect our broader commitment to advancing comprehensive cancer care for patients."

Highlights include:

Adjuvant treatment with Libtayo in adults with CSCC with high risk of recurrence after surgery and radiation: Late-breaking overall survival (OS) data at approximately 3.5 years follow-up from the C-POST Phase 3 trial will provide further evidence supporting Libtayo as the standard of care in this indication.
Neoadjuvant treatment with Libtayo in stage II-IV CSCC: Data include the final analysis of Phase 2 results, which represent the most mature data set in patients treated with Libtayo prior to surgery.
Factor XI antibodies (cenvacibart and amrecibart) as a potential approach to reducing thrombosis in patients with cancer: Data include a Phase 2 sub-analysis and modeling in catheter-related VTE, plus an update on the Phase 3 ROXI-CAT-II trial.

The full list of Regeneron presentations at ESMO (Free ESMO Whitepaper) are as follows: 

Abstract Title Abstract Presenter Session Date/Time (CET)
Skin Cancer
C-POST Phase 3 trial of adjuvant cemiplimab vs. placebo for high-risk CSCC: OS update at approximately 3.5 years’ median follow-up LBA: 59
Danny Rischin Sunday
October 25,
10:15-11:45
A Phase 2 study of neoadjuvant cemiplimab for Stage II–IV CSCC: final analysis Poster presentation: 2490P Neil D. Gross Saturday
October 24,
12:00-12:45
Long-term Overall Survival (OS) with Fianlimab (FIAN) plus Cemiplimab (Cemi) in Advanced Melanoma (aMel): Survival Follow-up of a Phase 1 Study Poster presentation: 2091P Omid Hamid Saturday
October 24,
12:00-12:45
Lung Cancer
Impact of objective response on PROs in patients receiving cemiplimab + chemotherapy vs. placebo + chemotherapy for aNSCLC: EMPOWER-Lung 3 Part 2 Poster presentation: 2714P Konstantin Penkov Monday
October 26,
12:00-12:45
CEMI-LUNG, a European-based observational study to assess cemiplimab real world effectiveness and safety in patients with advanced non-small cell lung cancer Poster presentation: 2580P Jesus Corral Jaime Monday
October 26,
12:00-12:45
Ovarian Cancer
Circulating tumor DNA (ctDNA), cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) associate with survival outcomes in patients with platinum-resistant ovarian cancer treated with ubamatamab Poster presentation: 1957P Jung-Yun Lee Saturday
October 24,
12:00-12:45
A Phase 1/2 study of REGN5668 (ubamatamab) (mucin 16 [MUC16] × cluster of differentiation [CD]28 costimulatory bispecific antibody), in combination with other targeted therapies, in patients with recurrent ovarian cancer or endometrial cancer: Trial in progress update ePoster presentation: 1445eTiP Roisin E. O’Cearbhaill N/A
Thrombosis (cenvacibart [REGN7508] and amrecibart [REGN9933])
Phase 3 trial-in-progress evaluating cenvacibart for the treatment and secondary prevention of venous thromboembolism (VTE) in participants with solid and hematologic cancers (ROXI-CAT-II) ePoster presentation: 1534eTiP Andrés J. Muñoz N/A
Sub-analysis of a Phase 2 study investigating amrecibart and cenvacibart for the prevention of contact-mediated VTE in participants with active cancer undergoing peripherally inserted central catheter (PICC) placement (ROXI-CATH) Poster presentation: 1468P Jeffrey I. Zwicker Monday
October 26,
12:00-12:45
Population pharmacokinetic/pharmacodynamic modeling of REGN7508Cat in patients with a PICC from ROXI-CATH who have active cancer supports maximal Factor XI pathway inhibition Poster presentation: 3968P Jeffrey I. Zwicker Saturday
October 24,
12:00-12:45

The potential uses of neoadjuvant Libtayo in CSCC, ubamatamab, cenvacibart and amrecibart described above are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.

(Press release, Regeneron, OCT 6, 2026, View Source [SID1234673246])